NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders-medium-term follow-up and clinical course.

A study of olanzapine versus placebo showed trend-level benefits for reducing transition rate in favour of olanzapine after 12 months, although the difference did not reach statistical significance. 25 At 2-year follow-up transition rate did not differ between the two groups. 26 Bechdolf and colleagues 27 reported that an integrated psychological intervention was superior to supportive counselling in high-risk patients at 24-month follow-up.

also in 111,027 other papers